Concepedia

Sylvia Haas

SH

118

Publications

11.2K

Citations

47

H-Index

1971

Active since

Affiliations

Technical University of Munich(Current)

Thrombosis Research Institute

Bayer (Germany)

McMaster University

Harvard University

Sylvia Haas is an author at Technical University of Munich specializing in medicine, thrombosis, and pharmacotherapy.

ORCID

Top concepts

Publications per year

1971–2023

118

Publications

118

Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Hip Arthroplasty

Bengt I. Eriksson, Lars C. Borris, Richard J. Friedman et al. · New England Journal of Medicine · 2008 · 1.4K citations · Full text

Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial

Ajay K. Kakkar, Benjamin Brenner, Ola E. Dahl et al. · The Lancet · 2008 · 1.1K citations

, , +8

Apixaban versus Enoxaparin for Thromboprophylaxis in Medically Ill Patients

Samuel Z. Goldhaber, Alain Leizorovicz, Ajay K. Kakkar et al. · New England Journal of Medicine · 2011 · 542 citations · Full text

XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation

A. John Camm, Pierre Amarenco, Sylvia Haas et al. · European Heart Journal · 2015 · 447 citations · Full text

Risk Profiles and Antithrombotic Treatment of Patients Newly Diagnosed with Atrial Fibrillation at Risk of Stroke: Perspectives from the International, Observational, Prospective GARFIELD Registry

Ajay K. Kakkar, Iris Mueller, Jean‐Pierre Bassand et al. · PLoS ONE · 2013 · 440 citations · Full text

Rows per page

1–5 of 118